Jul 19, 2021 09:03 JST

Source: Eisai

Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand

TOKYO, Jul 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. This is the first launch of Goofice in the Asian region excluding Japan.

Goofice, which Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. (Tokyo, "EA Pharma"), in-licensed from Albireo AB (Sweden), is a once-daily, orally available constipation treatment with a novel action mechanism. Goofice inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon. The dual action of moisture secretion and bowel movement promotion is expected to enhance natural defecation.

The prevalence of constipation is high in young women as well as in both elderly men and women. In Thailand, the number of patients with the prevalence of self-defined constipation is estimated to be about 10 million1, and it is predicted that the number of patients will increase year by year as the population ages. In constipation, symptoms such as sensation of incomplete evacuation and hard stools appear in addition to reduction of bowel movement frequency. When such symptoms become chronic, many patients suffer a decline in QOL (quality of life).

In Japan, EA Pharma and Mochida Pharmaceutical Co., Ltd. (Tokyo) respectively market the product under the same brand name, and Eisai is co-promoting with EA Pharma. In Asia (Thailand, Indonesia, Philippines, Malaysia, and Singapore), Eisai is responsible for the commercialization and marketing of this product under a contract with EA Pharma.

Eisai will continue to make a further contribution to improve QOL for patients with chronic constipation in Thailand and other Asian countries, through maximization of the product value of Goofice.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment
July 29 2021 16:34 JST
 
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
July 27 2021 08:00 JST
 
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
July 23 2021 08:17 JST
 
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
July 21 2021 09:34 JST
 
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
July 01 2021 10:43 JST
 
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
June 24 2021 11:00 JST
 
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma
June 23 2021 14:20 JST
 
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
June 18 2021 14:02 JST
 
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 15 2021 08:00 JST
 
Eisai Receives Special Prize at Platinum Career Award 2021
June 09 2021 12:44 JST
 
More Press release >>

Latest Press Release


More Latest Release >>